Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Naval Daver, MD reviews new targeted therapies transforming AML treatment in both young and older patient groups.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
A group of experts led by Naval Daver, MD discuss mutation loss, MRD dynamics, and transplant timing in evolving AML care.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
Dr. Swoboda discusses his role as clinical investigator of the QuANTUM-Wild study, how AI can transform oncology, and more.
The FDA has accepted a Supplemental New Drug Application for decitabine and cedazuridine plus venetoclax for AML.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025.
Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Section Editor
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.